Perspective Therapeutics, Inc.
CATX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | -0.02 | -0.09 | -0.19 |
| FCF Yield | -35.38% | -17.21% | -9.20% | -4.70% |
| EV / EBITDA | 14.15 | -5.36 | -7.73 | -14.88 |
| Quality | ||||
| ROIC | 3.15% | -46.45% | -28.73% | -11.07% |
| Gross Margin | 0.00% | 100.00% | 23.00% | 42.76% |
| Cash Conversion Ratio | 0.23 | 0.79 | 0.83 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -48.98% | -10.93% | 3.70% |
| Free Cash Flow Growth | -91.41% | -204.51% | -56.39% | -147.86% |
| Safety | ||||
| Net Debt / EBITDA | -5.50 | 0.17 | 1.41 | 8.08 |
| Interest Coverage | -217.90 | -487.39 | 0.00 | -62.11 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 3.88 | 5.79 |
| Cash Conversion Cycle | 0.00 | 299.08 | 61.22 | 68.74 |